

Barcelona, Spain

Annual Congress of the
European Association of Nuclear Medicine

October 12 – 16, 2019
Barcelona, Spain

Joint Symposium 20

Thyroid Committee / ETA-CRN - European Thyroid Association - Cancer Research Network (ETA-CRN) /
European Federation of Societies on Ultrasound in Medicine and Biology (EFSUMB)

Tuesday, October 15, 11:30-13:00

Session Title

Thyroid Cancer Imaging and Biomarkers

Chairpersons

Luca Giovanella (Bellinzona, Switzerland)

Maria Radzina (Riga, Latvia / EFSUMB)

Carla Colombo (Milan, Italy / ETA-CRN)

Programme

11:30 - 12:00 Carla Colombo (Milan, Italy / ETA-CRN): Molecular Biomarkers

12:00 - 12:30 Maija Radzina (Riga, Latvia / EFSUMB): Ultrasound and Cross-Sectional Radiology

12:30 - 13:00 Luca Giovanella (Bellinzona, Switzerland): Molecular Imaging and Circulating Biomarkers

Educational Objectives

Learn about the role, limits and pitfalls of molecular markers in thyroid cancer management

Learn about the role, limits and pitfalls of imaging in thyroid cancer management

Learn about the role, limits and pitfalls of circulating tumour markers in thyroid cancer management

Summary

Since thyroglobulin and calcitonin were first described as biomarkers for differentiated and medullary thyroid cancer, new biochemical and molecular biomarkers have been discovered. In addition, anatomic and functional imaging of thyroid cancer also developed dramatically and now hybrid imaging with both SPECT/CT and PET/CT and different radiopharmaceuticals can aid us to personalize thyroid cancer treatment (i.e. theragnostics). In coming years, there will be focus on new molecular targets, endoradiotherapies and genomic and proteomic technologies. The purpose of this symposium is to review the role, limits and pitfalls of currently available (imaging) markers of thyroid cancer.

Key Words

Thyroid cancer, biomarkers, radiology, nuclear medicine, molecular imaging